These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34963319)

  • 1. Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Jessee JK
    Ann Pharmacother; 2022 Aug; 56(8):951-957. PubMed ID: 34963319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
    J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melflufen for relapsed and refractory multiple myeloma.
    Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan flufenamide for relapsed/refractory multiple myeloma.
    Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG
    Drugs Today (Barc); 2022 Aug; 58(8):407-423. PubMed ID: 35983927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
    Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
    Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melphalan Flufenamide (Melflufen): First Approval.
    Dhillon S
    Drugs; 2021 Jun; 81(8):963-969. PubMed ID: 33961277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melflufen for the treatment of multiple myeloma.
    Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
    Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
    Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
    Schjesvold FH; Ludwig H; Mateos MV; Larocca A; Abdulhaq H; Norin S; Thuresson M; Bakker NA; Richardson PG; Sonneveld P
    Eur J Haematol; 2024 Mar; 112(3):402-411. PubMed ID: 37968873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
    Bringhen S; Voorhees PM; Plesner T; Mellqvist UH; Reeves B; Sonneveld P; Byrne C; Nordström E; Harmenberg J; Obermüller J; Richardson PG
    Br J Haematol; 2021 Jun; 193(6):1105-1109. PubMed ID: 33403663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
    Pour L; Szarejko M; Bila J; Schjesvold FH; Spicka I; Maisnar V; Jurczyszyn A; Grudeva-Popova Z; Hájek R; Usenko G; Thuresson M; Norin S; Jarefors S; Bakker NA; Richardson PG; Mateos MV
    Haematologica; 2024 Mar; 109(3):895-905. PubMed ID: 37646660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
    Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L
    Haematologica; 2024 Mar; 109(3):867-876. PubMed ID: 37646657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
    Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
    Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
    Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M
    J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
    Sonneveld P; Richardson PG; Ludwig H; Dimopoulos MA; Schjesvold FH; Hájek R; Abdulhaq H; Thuresson M; Norin S; Bakker NA; Mateos MV
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):687-696. PubMed ID: 37355418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.
    Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32992506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo activity of melflufen (J1)in lymphoma.
    Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
    BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
    Larocca A; Leleu X; Touzeau C; Bladé J; Paner A; Mateos MV; Cavo M; Maisel C; Alegre A; Oriol A; Raptis A; Rodriguez-Otero P; Mazumder A; Laubach J; Nadeem O; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG
    Br J Haematol; 2022 Feb; 196(3):639-648. PubMed ID: 34671975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
    Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
    Cells; 2022 May; 11(9):. PubMed ID: 35563880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.